Sign up USA
Proactive Investors - Run By Investors For Investors

M Pharma predicts spate of product launches will lead to dramatic rise in revenues

The company has begun commercial discussions with multiple partners in the Eastern European community), Mexico, Brazil and Australia
Rising sales
M Pharma has plans to launch multiple new branded products in numerous North American sales channels this year

Shares in M Pharmaceutical Inc (CNSX:MQ, OTCMKTS:MPHMF) shot up on Friday morning as the drugs developer raised revenue guidance for this quarter and the next.

Having looked at the order books and factoring in planned product launches from its established distribution partners, including branded product launches in the USA and Canada, plus sales to new distribution/marketing partners outside of North America, M felt confident enough to predict a dramatic increase in revenues for next year and beyond.

M Pharma was recently informed that one of its customers has received new product approvals in new foreign markets, both in the Americas and in Asia, and will be launching operations in those markets in the third quarter and fourth quarter of 2017.

READ M Pharma completes 40J's acquisition on schedule

READ M Pharmaceutical piecing together the jigsaw of success

In addition to the expansion into new markets, M Pharma is in late-stage discussions with some current business partners for the sale of newly developed topical formulations of its menthol and L-arginine technology, in multiple topical formats (e.g. skin patches) for a variety of treatment conditions.

Lastly, M Pharma said it would be renewing its push to be more integrated with the current distribution partners in their marketing and sales initiatives, road shows, sales meetings, distributor events, and other means to help drive sales of M Pharma technologies.

M Pharma has plans to launch multiple new branded products in numerous sales channels in the United States and Canadian markets in the third quarter and fourth quarter of 2017, with additional product line launches in 2018 to advance top-line revenues and profitability.

These multiple pipeline products were acquired from 40J's LLC earlier this year and represent only a sample of the technologies currently working their way to commercialization, the company said.

Shares in M Pharma were up by a fifth to C$0.06 in lunchtime trading.

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
1537236236_main-better-use.jpg
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use